PLGA Microspheres Coated with Cancer Cell-Derived Vesicles for Improved Internalization into Antigen-Presenting Cells and Immune Stimulation

Jung, Heesun; Jang, Hyo-Eun; Kang, Yoon Young; Song, Jae Bok; Mok, Hyejung

doi:10.1021/acs.bioconjchem.9b00240

Cited by 16 publications

(9 citation statements)

References 41 publications

(103 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 14,15 ] Accordingly, cell‐derived VEs have been adopted as carriers and as coating materials for nanoparticles with drugs for selective drug delivery. [ 16,17 ] Recently, hybrid VEs comprising two types of cell‐derived VEs (e.g., red blood cell (RBC)–B16‐F10 hybrid membrane) and synthetic liposome/cell‐derived membranes (e.g., C6 glioma cell membranes/liposomes) have been reported for homotypic targeting and long circulation. [ 10,18 ] However, hybrid VEs comprising two types of cancer cells for dual targeting to two types of tumors have not yet been reported.…”

Section: Introductionmentioning

confidence: 99%

Cancer‐Cell‐Derived Hybrid Vesicles from MCF‐7 and HeLa Cells for Dual‐Homotypic Targeting of Anticancer Drugs

Song

Jung

You

et al. 2021

Macromolecular Bioscience

Self Cite

View full text Add to dashboard Cite

Here, as a proof of concept, hybrid vesicles (VEs) are developed from two types of cancer cells, MCF-7 and HeLa, for the dual targeting of the anticancer drug doxorubicin (Dox) to cancer cells via homotypic interactions. Hybrid VEs with a size of 181.8 ± 28.2 nm and surface charge of −27.8 ± 1.9 mV are successfully prepared by the fusion of MCF-7 and HeLa VEs, as demonstrated by the fluorescence resonance energy transfer assay. The hybrid VEs exhibit enhanced intracellular uptake both in MCF-7 and HeLa cells. Dox-encapsulated hybrid VEs (Dox-hybrid VEs) also exhibit promising anticancer and antiproliferative activities against MCF-7/multidrug-resistant cells and HeLa cells. In addition, compared to free Dox, the Dox-hybrid VEs exhibit low intracellular uptake and reduced cytotoxicity for RAW264.7 cells. Thus, hybrid VEs with dual-targeting activity toward two types of cancer cells may be useful for the specific targeting of anticancer drugs for improved anticancer effects with reduced nonspecific toxicity.

show abstract

Section: Introductionmentioning

confidence: 99%

Cancer‐Cell‐Derived Hybrid Vesicles from MCF‐7 and HeLa Cells for Dual‐Homotypic Targeting of Anticancer Drugs

Song

Jung

You

et al. 2021

Macromolecular Bioscience

Self Cite

View full text Add to dashboard Cite

show abstract

“…These studies revealed that MPLA-loaded PLGA MPs coated with cancer cells form cancer cell-derived vesicles (MS-VEs) that were more efficiently engulfed by APCs compared with noncoated microspheres. In addition, incorporation of MPLA within MS-VEs triggered elevated release of immune stimulating cytokines from macrophages and dendritic cells compared to free MPLA . Together, these studies suggest that polymer particles coated with cancer-derived cell membranes can induce efficient immune responses, and this response could be further amplified by incorporating immune signals in the core material.…”

Section: Learning From Cancer Immunotherapy To Improve Vaccine Agains...mentioning

confidence: 81%

Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases

Yenkoidiok-Douti

Jewell

2020

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Despite the success of vaccines in preventing many infectious diseases, effective vaccines against pathogens with ongoing challenges -such as HIV, malaria, and tuberculosis -remain unavailable. The emergence of new pathogen variants, the continued prevalence of existing pathogens, and the resurgence of yet other infectious agents motivate the need for new, interdisciplinary approaches to direct immune responses. Many current and candidate vaccines, for example, are poorly immunogenic, provide only transient protection, or create risks of regaining pathogenicity in certain immune-compromised conditions. Recent advances in biomaterials research are creating new potential to overcome these challenges through improved formulation, delivery, and control of immune signaling. At the same time, many of these materials systems -such as polymers, lipids, and self-assembly technologies -may achieve this goal while maintaining favorable safety profiles. This review highlights ways in which biomaterials can advance existing vaccines to safer, more efficacious technologies, and support new vaccines for pathogens that do not yet have vaccines. Biomaterials that have not yet been applied to vaccines for infectious disease are also discussed, and their potential in this area is highlighted

show abstract

“…This MS-VE could serve as a platform system for delivering immune stimulators and antigens to antigen-presenting cells with negligible toxicity. RNA interference (RNAi) combined with immunogenic chemotherapy can elicit potent antitumor immunity against cancer cells (Jung et al, 2019).…”

Section: Polymer-based Nanovesicle Delivery In Conjunction With Immun...mentioning

confidence: 99%

Research Progress and Prospects for Polymeric Nanovesicles in Anticancer Drug Delivery

Zhang

Chen

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Polymeric vesicles served as the most promising candidates of drug delivery nanocarriers are attracting increasing attention in cancer therapy. Significant advantages have been reported, including hydrophilic molecules with high loading capacity, controllable drug release, rapid and smart responses to stimuli and versatile functionalities. In this study, we have made a systematic review of all aspects of nano-vesicles as drug delivery vectors for cancer treatment, mainly including the following aspect: characteristics of polymeric nanovesicles, polymeric nanovesicle synthesis, and recent progress in applying polymeric nanovesicles in antitumor drug delivery. Polymer nanovesicles have the advantages of synergistic photothermal and imaging in improving the anticancer effect. Therefore, we believe that drug carrier of polymer nanovesicles is a key direction for cancer treatment.

show abstract

PLGA Microspheres Coated with Cancer Cell-Derived Vesicles for Improved Internalization into Antigen-Presenting Cells and Immune Stimulation

Cited by 16 publications

References 41 publications

Cancer‐Cell‐Derived Hybrid Vesicles from MCF‐7 and HeLa Cells for Dual‐Homotypic Targeting of Anticancer Drugs

Cancer‐Cell‐Derived Hybrid Vesicles from MCF‐7 and HeLa Cells for Dual‐Homotypic Targeting of Anticancer Drugs

Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases

Research Progress and Prospects for Polymeric Nanovesicles in Anticancer Drug Delivery

Contact Info

Product

Resources

About